Mein Warenkorb

BCMA

BCMA Molekülinformation

Englischer NameB-cell maturation proteinAnzahl der inverkehr gebrachten Arzneimittel8
Anzahl der klinischen Arzneimittel151Target-AliasB-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameB-cell maturation protein
Target-AliasB-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Anzahl der inverkehr gebrachten Arzneimittel8
Anzahl der klinischen Arzneimittel151
Höchste Forschungs- und EntwicklungsphaseApproved

BCMA Produktliste

  • Attribut

    Protein (31)Antibody (1)Beads (1)Cell Grade Beads (2)Kits (1)Cell (3)

  • Produktbibliothek

    Online (39)

  • Spezies

    Human (27)Cynomolgus / Rhesus macaque (5)Mouse (4)Rabbit (1)Rat (1)Canine (1)

  • Etikett

    Fc Tag (4)His Tag (19)Fc Tag & Avi Tag (3)Llama IgG Fc Tag (2)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)- (8)

  • Marker

    Unconjugated (17)FITC Labeled (3)Biotin-labeled (5)- (7)PE Labeled (2)APC Labeled (2)AF488 Labeled (1)AF647 Labeled (1)AF555 Labeled (1)

BCMA Molekülhintergrund

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

BCMA Molekülalias

TNFRSF17,CD269,BCM,BCMA

Antikörperprojekt-Handelsplattform

ProjektnameProjektphaseMolekültypMolekülquelleKrankheitsgebietIndikationen
BCMA VHH - 01LeadMonoclonalNanobodyHematological MalignancyMultiple myeloma

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University)Phase 3 ClinicalThe First Affiliated Hospital Of Soochow UniversityLeukemia; Multiple Myeloma
Details
Anitocabtagene autoleucelKite-772; CART-ddBCMAPhase 3 ClinicalArcellx IncAutoimmune Diseases; Autoimmune Diseases of the Nervous System; Multiple Myeloma; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations
Details
EtentamigTNB-383B; ABBV-383Phase 3 ClinicalTeneoOne IncImmunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian)Descartes-08Phase 3 ClinicalCartesian Therapeutics IncAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-synthetase Syndrome; Dermatomyositis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
GC-012FAZD0120; GC-012F; GC012F; AZD-0120Phase 3 ClinicalGracell Biotechnologies (Shanghai) Co LtdAmyloidosis; Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis; Myositis; Scleroderma, Systemic
Details
BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)Phase 3 ClinicalPeking University People'S HospitalAcquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
RamantamigJNJ-79635322; JNJ-5322Phase 3 ClinicalJanssen Research & Development LlcMultiple Myeloma
Details
VelinotamigGR-1803Phase 3 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co LtdAutoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
GamgertamigCM-336; OM336Phase 3 ClinicalKeymed Biosciences Co LtdAmyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous
Details
BCMA CAR-T Cells (Pregene)PRG-1801; GLPG-5301; DRL-1801Phase 2 ClinicalShenzhen Pregene Biopharma Co LtdImmunoglobulin G4-Related Disease; Lupus Nephritis; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic
Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology)BCMA-CART; HR003Phase 2 ClinicalHrain Biotechnology Co LtdMultiple Myeloma
Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdLymphoma, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma
Details
BCMA CAR-T cell therapy (Chongqing Precision Biotech)Phase 2 ClinicalChongqing Precision Biotechnology Co LtdMultiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
Details
Anti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology)Phase 2 ClinicalShanghai Unicar-Therapy Bio-Medicine Technology Co LtdLeukemia; Multiple Myeloma
Details
C-CAR088C-CAR088Phase 2 ClinicalCellular Biomedicine (Shanghai) Co LtdMultiple Myeloma
Details
Orvacabtagene autoleucelET140-CAR; MCARH-171; JCARH-125; FCARH-143; ET-140Phase 2 ClinicalFred Hutchinson Cancer Research CenterMultiple Myeloma
Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)Phase 2 ClinicalPeople'S Liberation Army General Hospital Military ServiceMultiple Myeloma
Details
KQ-2003KQ-2003; KQ2003Phase 2 ClinicalShanghai Keqi Pharmaceutical Technology Co LtdMultiple Myeloma; POEMS Syndrome; Solid tumours
Details
Pamlectabart tismanitinHDP101-ATAC; HDM2027; HDP-101Phase 2 ClinicalHeidelberg Pharma AGHematologic Diseases; Multiple Myeloma; Paraproteinemias
Details
Anti BCMA CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology)Phase 2 ClinicalMinsk Scientific-Practical Center For Surgery, Transplantation And HematologyMultiple Myeloma
Details
Anti-BCMA-CD19 CAR-T cells therapy (Pla General Hospital)Phase 2 ClinicalPla General HospitalAutoimmune Diseases; Immunoglobulin G4-Related Disease
Details
BCMA CAR-T Cell Therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech)Phase 2 ClinicalEssen BiotechMultiple Myeloma
Details
SL-1703SL1703; SL-1703Phase 2 ClinicalHebei Senlang Biological Technology Co LtdLupus Nephritis; Multiple Myeloma; Scleroderma, Systemic
Details
VonsetamigREGN-5459Phase 2 ClinicalRegeneron Pharmaceuticals IncLupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic
Details
QT-019BQT-019BPhase 2 ClinicalHangzhou Qihan Biotechnology Co LtdAnemia, Hemolytic, Autoimmune; Autoimmune Diseases; Lupus Erythematosus, Systemic; Myasthenia Gravis
Details
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
ICG-318ICG-318; ICG318Phase 2 ClinicalSonghe Immunobiological Medical (Shenzhen) Co LtdLupus Erythematosus, Systemic; Lupus Nephritis
Details
BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)Phase 2 ClinicalThe First Affiliated Hospital Of Xiamen UniversityMultiple Myeloma
Details
BCD-248BCD-248Phase 2 ClinicalBIOCAD JSCMultiple Myeloma
Details
SENL-103SENL-103; S-103Phase 2 ClinicalHebei Senlang Biological Technology Co LtdAmyloidosis; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis
Details
Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)Phase 2 ClinicalShenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of HealthMultiple Myeloma; Plasmacytoma
Details
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech)Phase 2 ClinicalEssen BiotechAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Granulomatosis with Polyangiitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Sjogren's Syndrome
Details
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences)Phase 2 ClinicalShahid Beheshti University Of Medical SciencesMultiple Myeloma
Details
C-CAR168C-CAR168Phase 2 ClinicalCellular Biomedicine (Shanghai) Co LtdAutoimmune Diseases; Encephalitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Neuromyelitis Optica; Scleroderma, Systemic; Stiff-Person Syndrome
Details
IBI-3003IBI3003; IBI-3003Phase 2 ClinicalMultiple Myeloma
Details
BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)Phase 2 ClinicalGuangzhou Bio-Gene Technology Co LtdMultiple Myeloma
Details
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases HospitalMultiple Myeloma
Details
MBS-314MBS-314Phase 2 ClinicalBeijing Mabworks Biotech Co LtdMultiple Myeloma
Details
BelantamabGSK2857914; GSK-2857914Phase 2 ClinicalGlaxosmithkline PlcAutoimmune Diseases; Multiple Myeloma
Details
SNC-102 (Shanghai Simnova Biotechnology)SNC102; CART-BCMAPhase 2 ClinicalShanghai Simnova Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma
Details
TQB-2934TQB2934; TQB-2934Phase 2 ClinicalNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupAmyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell
Details
CAR-BCMA(Sheba Medical Center)Phase 2 ClinicalSheba Medical Center, IsraelMultiple Myeloma
Details
ARI-0002hARI-0002hPhase 2 ClinicalInstituto De Salud Carlos IiiMultiple Myeloma
Details
Descartes-11Descartes-11; Descartes-011Phase 2 ClinicalCartesian Therapeutics IncMultiple Myeloma
Details
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital)Phase 2 ClinicalShenzhen University General HospitalMultiple Myeloma
Details
F-182112F182112; F-182112Phase 2 ClinicalShandong New Time Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical)Phase 2 ClinicalShandong New Time Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
Revlucabtagene AutoleucelHBI-0101; NXC-201Phase 2 ClinicalHadassah Medical Organization, Immix Biopharma IncArthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myositis; Scleroderma, Systemic
Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology)Phase 2 ClinicalShanghai YaKe Biotechnology Co LtdMultiple Myeloma; Neoplasms
Details
PodentamigHPN-217; BCMA TriTACPhase 1 ClinicalAbbvie Inc, Harpoon TherapeuticsMultiple Myeloma
Details
ACTR 087/SEA BCMA combination therapyPhase 1 ClinicalUnum Therapeutics IncMultiple Myeloma
Details
bb-21217bb-21217Phase 1 ClinicalBristol-Myers Squibb Company, Genetix Biotherapeutics IncMultiple Myeloma
Details
AMG-224AMG-224Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
Nendocabtagene onogedleucelALLO-715Phase 1 ClinicalCellectis SaMultiple Myeloma
Details
AlnuctamabEM-901; BMS-986349; CC-93269Phase 1 ClinicalEngmab AgLupus Erythematosus, Systemic; Multiple Myeloma
Details
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University)Phase 1 ClinicalThe First Affiliated Hospital Of Nanchang UniversityMultiple Myeloma
Details
PavurutamabAMG-701Phase 1 ClinicalAmgen IncMultiple Myeloma
Details
CART-BCMAMTV-273; CART-BCMAPhase 1 ClinicalUniversity Of PennsylvaniaKidney Failure, Chronic; Multiple Myeloma; Rejection of renal transplantation; Renal Insufficiency
Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdLupus Erythematosus, Systemic; Multiple Myeloma; Pancytopenia; Waldenstrom Macroglobulinemia
Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology)Phase 1 ClinicalShengyan Pharmaceutical TechnologyMultiple Myeloma
Details
SA102-CAR-TSA-102; SA102Phase 1 ClinicalWuhan Sian Biotechnology Co LtdMultiple Myeloma
Details
DXC-009DXC-009Phase 1 ClinicalHangzhou Dac Biotech Company LtdMultiple Myeloma
Details
ACLX-001ACLX-001Phase 1 ClinicalArcellx IncMultiple Myeloma
Details
CB-011CB-011Phase 1 ClinicalCaribou Biosciences IncMultiple Myeloma
Details
FT-576FT-576Phase 1 ClinicalFate Therapeutics Inc, University Of MinnesotaBone Marrow Neoplasms; Multiple Myeloma
Details
P-BCMA-ALLO1P-BCMA-ALLO1; RG-6538Phase 1 ClinicalJanssen Biotech Inc, Transposagen Biopharmaceuticals IncMultiple Myeloma
Details
Allogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital)Phase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Erythematosus, Systemic; Myositis; Scleroderma, Systemic; Thrombocytopenia
Details
BCMA-Targeted CAR T-Cell therapy (Chulalongkorn University)Phase 1 ClinicalChulalongkorn UniversityMultiple Myeloma
Details
CAR BCMA-CD70-T cells therapy (The Fifth Medical Center Of Pla General Hospital)Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)Neoplasms, Plasma Cell
Details
CD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University)Phase 1 ClinicalWest China Hospital Of Sichuan UniversityAutoimmune Diseases
Details
O&D-001O&D-001Phase 1 ClinicalO&D BioTech Group Co LtdMultiple Myeloma
Details
Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital)Phase 1 ClinicalBeijing Gao Boren Hospital Co LtdAnemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Multiple Sclerosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
IASO-206IASO206; IASO-206Phase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalMultiple Myeloma
Details
UCAR T-cell therapy (The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic
Details
Fully-Human Anti-BCMA CAR therapy (NIH)Phase 1 ClinicalNational Cancer InstituteMultiple Myeloma
Details
NPB5005-V283NPB5005-V283Phase 1 ClinicalNeomics Pharmaceuticals LLCMultiple Myeloma
Details
CAR19-BCMA dual-target CAR-T cell therapy (Tahoe Chunyu Biotechnology)Phase 1 ClinicalHebei Tahoe Chunyu Biotechnology Co LtdMultiple Myeloma
Details
TPST-2003TPST-2003Phase 1 ClinicalFactor Bioscience IncMultiple Myeloma
Details
Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics)KN-3601; KN3601Phase 1 ClinicalShenzhen Rui Therapeutics Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic; Sjogren's Syndrome
Details
KT-501KT501; KT-501Phase 1 ClinicalKali Therapeutics IncArthritis, Rheumatoid
Details
Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital)CT103dPhase 1 ClinicalInstitute Of Hematology & Blood Diseases HospitalLeukemia, Plasma Cell; Multiple Myeloma
Details
Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello)Phase 1 ClinicalUcello Therapeutics Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
QM-103QM-103; QM103Phase 1 ClinicalBeijing Qimai Yonghua Biotechnology Co LtdMultiple Myeloma
Details
RN-1201RN-1201; RN1201Phase 1 ClinicalThe First Affiliated Hospital Of Soochow UniversityThrombocytopenia
Details
OriV-508OriV508; OriV-508Phase 1 ClinicalWuhan Medical Care Center For Women And ChildrenLymphoma, Non-Hodgkin; Multiple Myeloma
Details
Meta10-BCMAMeta10-BCMAPhase 1 ClinicalAnhui Provincial HospitalImmunoglobulin Light-chain Amyloidosis; Leukemia, Plasma Cell; Multiple Myeloma
Details
SL-0439SL0439; SL-0439Phase 1 ClinicalHebei Senlang Biological Technology Co LtdMultiple Myeloma
Details
RN-1101 (Rui Therapeutics)RN-1101Phase 1 ClinicalShenzhen Rui Therapeutics Co LtdLymphoma, B-Cell; Multiple Myeloma
Details
CAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital))Phase 1 ClinicalThe Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)Neoplasms, Plasma Cell
Details
Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine)KN5601; KN-5601Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineArthritis; Autoimmune Diseases; Glomerulonephritis, IGA; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Mucocutaneous Lymph Node Syndrome; Nephrosis; Rheumatic Diseases
Details
RD06-05RD06-05Phase 1 ClinicalNanjing Bioheng Biotech Co LtdAnemia, Hemolytic, Autoimmune; Anti-Glomerular Basement Membrane Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Encephalitis; Evans syndrome; Glomerulonephritis; Graves Disease; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Multiple Sclerosis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic; Scleroderma, Systemic
Details
CT-0596CT-0596; CT0596Phase 1 ClinicalCarsgen Biomedicine (Shanghai) Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
68Ga-BC168Ga-BC1Phase 1 ClinicalThe First Affiliated Hospital Of Beijing UniversityMultiple Myeloma; Neoplasms, Plasma Cell
Details
UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center)Phase 1 ClinicalUniversity Hospitals Cleveland Medical CenterMultiple Myeloma
Details
ESO-T01ESO-T01Phase 1 ClinicalEsoBiotec SAMultiple Myeloma
Details
REVO-UWD-00BREVO-UWD-00B; UWD-00BPhase 1 ClinicalWondercel Therapeutics Co LtdMultiple Myeloma
Details
Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine)Phase 1 ClinicalThe Children'S Hospital, Zhejiang University School Of MedicineLupus Erythematosus, Systemic; Nephrosis
Details
PRG-2311PRG-2311Phase 1 ClinicalShenzhen Pregene Biopharma Co LtdImmunoglobulin G4-Related Disease; Lupus Nephritis
Details
BZE-2204BZE2204; BZE-2204Phase 1 ClinicalShanghai Cell Therapy Group Co LtdLupus Erythematosus, Systemic; Lymphoma, B-Cell; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic
Details
OL-101OL-101Phase 1 ClinicalOverland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityLupus Erythematosus, Systemic; Lupus Nephritis
Details
QLS-4131QLS-4131; QLS4131Phase 1 ClinicalQilu Pharmaceutical Co LtdLupus Erythematosus, Systemic; Multiple Myeloma
Details
Zirconium-89 belantamab89Zr-GSK2857914Phase 1 ClinicalGlaxosmithkline PlcMultiple Myeloma; Neoplasms
Details
RD-140RD140Phase 1 ClinicalNanjing Iaso Biotherapeutics Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
BCMA CAR-NK (Hrain Biotechnology)HR012Phase 1 ClinicalHrain Biotechnology Co LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital)Phase 1 ClinicalWuhan Union HospitalLupus Erythematosus, Systemic
Details
SYS-6020SYS6020; SYS-6020Phase 1 ClinicalCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co LtdLupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis
Details
KLN-1010KLN-1010Phase 1 ClinicalKelonia Therapeutics IncBlood Protein Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases
Details
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine)FKC-288; FKC288Phase 1 ClinicalNanjing University School Of MedicineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, Membranous; Immunoglobulin G4-Related Disease; Lupus Nephritis
Details
YKST-02YKST02; YKST-02Phase 1 ClinicalExcyte Biopharma LtdMultiple Myeloma
Details
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics)BMS-986453Phase 1 ClinicalJuno Therapeutics IncMultiple Myeloma
Details
SIM-0500SIM-0500; SIM0500Phase 1 ClinicalSimcere Pharmaceutical Group LtdBone Marrow Neoplasms; Multiple Myeloma
Details
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)Phase 1 ClinicalHualan Genetic Engineering (Henan) Co LtdMultiple Myeloma
Details
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)CBG-002 CAR-TPhase 1 ClinicalCarbiogene Therapeutics Co LtdMultiple Myeloma
Details
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma)SWK001; SWK-001Phase 1 ClinicalHunan Siweikang Pharmaceutical Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T (Nanjing Kati Medical Technology)Phase 1 ClinicalNanjing Kati Medical Technology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma)Phase 1 ClinicalActavis Inc, Eugia Pharma Specialities LtdMultiple Myeloma
Details
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co)Phase 1 ClinicalMultiple Myeloma
Details
BRL-302BRL-302Phase 1 ClinicalBRL Medicine IncAutoimmune Diseases; Lupus Nephritis; Multiple Sclerosis; Myasthenia Gravis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details
MCARH-125MCARH-125Phase 1 ClinicalMemorial Sloan Kettering Cancer CenterMultiple Myeloma
Details
ISB-2001ISB-2001; ABBV-2001Phase 1 ClinicalIchnos Sciences SaMultiple Myeloma
Details
OriC-321OriC-321; Ori-C-321Phase 1 ClinicalOriCell Therapeutics Co Ltd, Zhejiang UniversityMultiple Myeloma
Details
HY-027HY-027Phase 1 ClinicalJuventas Cell Therapy LtdMultiple Myeloma
Details
MEDI-2228MEDI-2228Phase 1 ClinicalMedimmune LlcMultiple Myeloma
Details
IBI-346IBI-346Phase 1 ClinicalMultiple Myeloma
Details
BCMA-NKEBCMA-NKEPhase 1 ClinicalBristol-Myers Squibb CompanyMultiple Myeloma
Details
KJ-C2111CT-0590; KJ-C2111Phase 1 ClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
PHE-885PHE-885Phase 1 ClinicalNovartis Pharma AgHematologic Neoplasms; Multiple Myeloma
Details
MCM-998MCM-998; LXG-250Phase 1 ClinicalNovartis Pharma AgMultiple Myeloma
Details
ALLO-605ALLO-605; ALLO605Phase 1 ClinicalCellectis Sa, Overland Pharmaceuticals (Shanghai) Co LtdMultiple Myeloma
Details
AUTO-8AUTO-8Phase 1 ClinicalAutolus Therapeutics PlcMultiple Myeloma
Details
CizutamigEMB-06; CND-106; CN106Phase 1 ClinicalShanghai Epimab Biotherapeutics, IncColitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic
Details
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University)Phase 1 ClinicalSichuan UniversityMultiple Myeloma
Details
JWCAR129JWCAR129; JWCAR-129Phase 1 ClinicalSuzhou Yaomingjunuo Biotechnology Co LtdMultiple Myeloma
Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital)Phase 1 ClinicalChongqing Xinqiao HospitalMultiple Myeloma
Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech)LCAR-BCXPhase 1 ClinicalMultiple Myeloma
Details
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd, Zhejiang UniversityAutoimmune Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome
Details
C-4-29Phase 1 ClinicalChongqing Precision Biotechnology Co LtdCarcinoma, Renal Cell; Lupus Erythematosus, Systemic; Multiple Myeloma
Details
CC-98633CC-98633Phase 1 ClinicalCelgene CorpMultiple Myeloma
Details
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology)ClinicalWuhan BioRaid Biotechnology Co LtdHematologic Neoplasms
Details
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)ClinicalHuazhong University Of Science And TechnologyMultiple Myeloma
Details
ECAR-01ECAR-01; ECAR01ClinicalAnhui Provincial HospitalAutoimmune Diseases
Details
CT-059XCT-059X; CT059XClinicalCARsgen Therapeutics Holdings LtdLeukemia, Plasma Cell; Multiple Myeloma
Details
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics)ACT-001(Acellytron Therapeutics)ClinicalAcellytron TherapeuticsMultiple Myeloma
Details
Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics)ClinicalMultiple Myeloma
Details
PD-1Ab21-BCMACAR-T (CD biopharma)CD-003; CD-203ClinicalCD (Suzhou) Biopharma Co LtdMultiple Myeloma
Details
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)UTAA17ClinicalPersongen Biotherapeutics (Suzhou) Co LtdMultiple Myeloma
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Belantamab mafodotinGSK-2857916; GSK2857916ApprovedGlaxosmithkline PlcBLENREPUnited StatesMultiple MyelomaGlaxosmithkline Plc2020-08-05Amyloidosis; Blood Protein Disorders; Bone Marrow Neoplasms; Corneal Diseases; Immunoglobulin Light-chain Amyloidosis; Lymphoma, B-Cell; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Paraproteinemias; Plasmablastic Lymphoma; Plasmacytoma
Details
Idecabtagene vicleucelbb-2121ApprovedGenetix Biotherapeutics IncAbecmaUnited StatesMultiple MyelomaCelgene Corp2021-03-26Multiple Myeloma
Details
Zevorcabtagene AutoleucelCT-053-CARsgenApprovedCarsgen Biomedicine (Shanghai) Co Ltd赛恺泽Mainland ChinaMultiple MyelomaKaixing Life Technology (Shanghai) Co Ltd2024-02-23Multiple Myeloma
Details
Equecabtagene AutoleucelCT-103A; CT103A; IBI-326ApprovedInnovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd福可苏, FUCASOMainland ChinaMultiple MyelomaNanjing Xunlu Biomedicine Co Ltd2023-06-30Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Encephalitis; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Myeloma; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Myositis; Neuromyelitis Optica; POEMS Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
TeclistamabJNJ-64007957; JNJ-64007959; JNJ-7957ApprovedGenmab A/S, Johnson & Johnson Innovative MedicineTECAYLI, TECVAYLI, 泰立珂EUMultiple MyelomaJanssen-Cilag International Nv2022-08-23Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Smoldering Multiple Myeloma
Details
Ciltacabtagene autoleucelJNJ-4528; LCAR-B38M; JNJ-68284528ApprovedCarvykti, 卡卫荻United StatesMultiple MyelomaNanjing Legend Biotechnology Co Ltd, Janssen Research & Development Llc2022-02-28Multiple Myeloma
Details
LinvoseltamabREGN-5458ApprovedRegeneron Pharmaceuticals IncLynozyficEUMultiple MyelomaRegeneron Ireland Designated Activity Company2025-04-23Food Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Renal Insufficiency, Chronic; Smoldering Multiple Myeloma
Details
ElranatamabPF‑3135; RN-613; PF-06863135ApprovedPfizer IncElrexfio, ELREXFIO™, ELREXFIOUnited StatesMultiple MyelomaPfizer Inc2023-08-14Anemia, Hemolytic, Autoimmune; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Smoldering Multiple Myeloma; Spinal Cord Diseases
Details

Produktrezensionen

  • C***e2026-09-03
    0Menschen mögen
    APC-Labeled Human BCMA (CAT# BCA-HA2H5-200tests) is well stocked with shipments typically less than 3 days after ordering. Our regional sales representative is very attentive and has been a useful resource in tracking orders when working on a tight schedule. The APC-Labeled Human BCMA works wonderfully. This is a directly conjugated material, thus no need for a secondary antibody so it can simply your experimental design and reduce the complexity of your experimental variables when designing your experiment's working range. A dilution series from their recommended 1:50, dilution sill performed well in flow cytometry well ~200 dilution (8x more dilute than recommended) and still detected positive cells at a 1:800 dilution (16-fold higher dilution than recommended) where I ended the titration series. Note- Your experimental setup may have different optimum dilutions, depending on your setup and goals. There was no non-specific binding, thus enabling minimal PBS washes and potentially allows for less cells to be utilized as some fraction will be lost each wash. I'm very pleased with the product, it will simplify assay design and reduce development time.
  • T***d2025-06-13
    0Menschen mögen
    Group used this product in a TE experiment on the MSD platform. Achieved a STD Curve range that was adequate for assay needs.
  • S***i2025-01-23
    1Menschen mögen
    We have repurchased this item dozens of time. This product is very effective for flow cytometry and we use it to help detect our BCMA CAR-T product.
Laden Sie mehr
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns